Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression, and aromatase inhibitors can drastically reduce circulating estrogen, increasing bone loss and fracture risk. Because most women with early breast cancer will live for many years, it is important to protect bone health during cancer therapy. Several recent clinical trials combining adjuvant endocrine therapy with bisphosphonates have demonstrated efficacy for preventing cancer treatment-induced bone loss in pre- and postmenopausal women with early breast cancer. The largest body of evidence supporting the use of adjuvant bisphosphonates comes from studies with zoledronic acid; however, studies with risedronate, ibandronate, and denosumab (a biologic agent) have also demonstrated efficacy for preventing bone loss. Adding zoledronic acid to endocrine therapy prevents bone loss and improves bone mineral density (BMD). In addition, preclinical studies suggest that bisphosphonates have direct and indirect antitumor activity, such as inducing tumor cell apoptosis, reducing tumor cell adhesion and invasion, reducing angiogenesis, activating immune responses, and synergy with chemotherapy agents, among others. Clinical trials have demonstrated significantly improved disease-free survival in patients receiving adjuvant endocrine therapy plus zoledronic acid compared with endocrine therapy alone. Ongoing studies will further define the role of adjuvant bisphosphonates in maintaining bone health and improving clinical outcomes. The available evidence suggests that pre- and postmenopausal patients may receive clinical benefit from including bisphosphonates as part of their adjuvant treatment regimen for endocrine-responsive early breast cancer.
Aapro, M., Abrahamsson, P.A., Body, J.J., Coleman, R.E., Colomer, R., Costa, L. et al. (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol19: 420-432.
2.
Aft , R., Naughton, M., Ylagan, L., Watson, M., Chavez-Macgregor, M., Trinkaus, K. et al. (2008) Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. Poster session presented at: 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago, IL. Abstract 1021.
3.
American Cancer Society (2007) Breast cancer facts & figures 2007-2008, American Cancer Society, Inc: Atlanta, GA.
4.
Anderson, W.F., Chatterjee, N., Ershler, W.B. and Brawley, O.W. ( 2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat76: 27-36.
5.
Bines, J., Oleske, D.M. and Cobleigh, M.A. ( 1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol14: 1718-1729.
6.
Boyle, W.J., Simonet, W.S. and Lacey, D.L. ( 2003) Osteoclast differentiation and activation. Nature423: 337-342.
7.
Brodie, A., Lu, Q. and Long, B. ( 1999) Aromatase and its inhibitors. J Steroid Biochem Mol Biol69: 205-210.
8.
Brufsky, A., Bundred, N., Coleman, R., Lambert-Falls, R., Mena, R., Hadji, P. et al. (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist13: 503-514.
9.
Brufsky, A., Harker, W.G., Beck, J.T., Carroll, R., Tan-Chiu, E., Seidler, C. et al. (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol25: 829-836.
10.
Brufsky, A.M., Bosserman, L.D., Caradonna, R.R., Haley, B.B., Jones, C.M., Moore, H.C. et al. (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer9: 77-85.
11.
Bruning, P.F., Pit, M.J., de Jong-Bakker, M., van den Ende, A., Hart, A. and van Enk, A. ( 1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer61: 308-310.
12.
Clarke, M., Collins, R., Darby, S., Davies, C., Evans, V., Godwin, J. et al. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365: 1687-1717.
13.
Clezardin, P., Ebetino, F.H. and Fournier, P.G. ( 2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res65: 4971-4974.
14.
Confavreux, C.B., Fontana, A., Guastalla, J.P., Munoz, F., Brun, J. and Delmas, P.D. ( 2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone41: 346-352.
15.
Coxon, J.P., Oades, G.M., Kirby, R.S. and Colston, K.W. ( 2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation . BJU Int94: 164-170.
16.
Cummings, S.R., Browner, W.S., Bauer, D., Stone, K., Ensrud, K., Jamal, S. et al. (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. For the Study of Osteoporotic Fractures Research Group. N Engl J Med339: 733-738.
17.
Delmas, P.D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P. and Bremond, A. ( 1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol15: 955-962.
18.
Denoyelle, C., Hong, L., Vannier, J.P., Soria, J. and Soria, C. ( 2003) New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects . Br J Cancer88: 1631-1640.
19.
Eastell, R., Hannon, R.A., Cuzick, J., Dowsett, M., Clack, G. and Adams, J.E. ( 2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res21: 1215-1223.
20.
Eidtmann, H., Bundred, N., de Boer, R., Llombart, A., Davidson, N., Neven, P. et al. (2008). The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. Oral session presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 10-14; San Antonio, TX. Abstract 44.
21.
Ellis, G.K., Bone, H.G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J. et al. (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol26: 4875-4882.
22.
Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Cordiali Fei, P., Di Cosimo, S. et al. (2005) Zoledronic-acid-induced circulating level
23.
modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology69: 35-43.
24.
Frassoldati, A., Brufsky, A., Bundred, N., Lambert-Falls, R., Hadji, P., Schenk, N. et al. (2009) Effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST/ ZO-FAST trials. Poster session presented at: Primary Therapy of Early Breast Cancer 11th International Conference; 2009 Mar 11-14; St. Gallen, Switzerland. Abstract 132.
25.
Fuleihan, G.E.H., Salamoun, M., Mourad, Y.A., Chehal, A., Salem, Z., Mahfoud, Z. et al. (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab90: 3209-3214.
26.
Garcia, M., Jemal, A., Ward, E.M., Center, M.M., Hao, Y., Siegel, R.L. et al.(2007) Global cancer facts and figures 2007, American Cancer Society: Atlanta, GA.
27.
Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Kainberger, F., Kassmann, H., Piswanger-Solkner, J.C. et al. (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol9: 840-849.
28.
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C. et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med360: 679-691.
29.
Gnant, M.F.X., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M. et al. (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol25: 820-828.
30.
Greenspan, S.L., Brufsky, A., Lembersky, B.C., Bhattacharya, R., Vujevich, K.T., Perera, S. et al. (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol26: 2644-2652.
31.
Ha, T.C. and Li, H. ( 2007) Meta-analysis of clodronate and breast cancer survival . Br J Cancer96: 1796-1801.
32.
Hadji, P., Body, J.J., Aapro, M.S., Brufsky, A., Coleman, R.E., Guise, T. et al. (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol19: 1407-1416.
33.
Hershman, D.L., McMahon, D.J., Crew, K.D., Cremers, S., Irani, D., Cucchiara, G. et al. (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol26: 4739-4745.
34.
Hillner, B.E., Ingle, J.N., Chlebowski, R.T., Gralow, J., Yee, G.C., Janjan, N.A. et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol21: 4042-4057.
35.
Hines, S.L., Mincey, B.A., Sloan, J.A., Thomas, S.P., Chottiner, E., Loprinzi, C.L. et al. (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol27: 1047-1053.
36.
Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J.F. et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365: 60-62.
37.
Johnell, O. and Hertzman, P. ( 2006) What evidence is there for the prevention and screening of osteoporosis? Available at: www.euro.who.int/document/e88668.pdf
38.
Kanis, J.A. ( 2009) FRAX® WHO fracture risk assessment tool. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, http://www.shef.ac.uk/FRAX/index.htm
39.
Kanis, J.A., Johnell, O., Oden, A., Dawson, A., De Laet, C. and Jonsson, B. ( 2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int12: 989-995.
40.
Lester, J.E., Dodwell, D., Purohit, O.P., Gutcher, S.A., Ellis, S.P., Thorpe, R. et al. (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res14: 6336-6342.
41.
Li, C.I., Daling, J.R. and Malone, K.E. ( 2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol21: 28-34.
42.
Lin, A.Y., Park, J.W., Scott, J., Melisko, M., Goga, A., Moasser, M.M. et al. (2008) Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow . J Clin Oncol26(suppl): 20s, Abstract 559.
43.
Lindsay, R., Christiansen, C., Einhorn, T.A., McKay Hart, D., Ljunghall, S., Mautalen, C.A. et al. (1997) Who are candidates for prevention and treatment for osteoporosis?Osteoporos Int7: 1-6.
44.
Lower, E.E., Blau, R., Gazder, P. and Tummala, R. ( 1999) The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med8: 949-954.
45.
Mundy, G.R. ( 2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer2: 584-593.
46.
Muraro, M., Mereuta, O.M., Carraro, F., Madon, E. and Fagioli, F. ( 2007) Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol249: 63-72.
47.
National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: breast cancer. Version 1.2009 . Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. National Comprehensive Cancer Network, Inc. : Fort Washington, PA.
48.
National Osteoporosis Foundation (2008) Physician’s guide to prevention and treatment of osteoporosis. Available at: www.nof.org. National Osteoporosis Foundation: Washington, DC.
49.
Ottewell, P.D., Deux, B., Monkkonen, H., Cross, S., Coleman, R.E., Clezardin, P. et al. (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res14: 4658-4666.
50.
Ottewell, P.D., Monkkonen, H., Jones, M., Lefley, D.V., Coleman, R.E. and Holen, I. ( 2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst100: 1167-1178.
51.
Paget, S. ( 1889) The distribution of secondary growths in cancer of the breast. Lancet133: 571-573.
52.
Quiet, C.A., Ferguson, D.J., Weichselbaum, R.R. and Hellman, S. ( 1995) Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol13: 1144-1151.
53.
Rack, B.K., Jueckstock, J., Genss, E.-M., Schoberth, A., Schindlbeck, C., Strobl, B. et al. (2007) Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Breast Cancer Res Treat106(suppl 1): S40, Abstract 511.
54.
Reid, D.M., Doughty, J., Eastell, R., Heys, S.D., Howell, A., McCloskey, E.V. et al. (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev34(suppl 1): S3-S18.
55.
Rogers, M.J., Gordon, S., Benford, H.L., Coxon, F.P., Luckman, S.P., Monkkonen, J. et al. (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer88: 2961-2978.
56.
Rosen, P.P., Groshen, S. and Kinne, D.W. ( 1991) Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol9: 1650-1661.
57.
Rosen, P.P., Groshen, S., Saigo, P.E., Kinne, D.W. and Hellman, S. ( 1989) Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with
58.
median follow-up of 18 years. J Clin Oncol7: 1239-1251.
59.
Saarto, T., Vehmanen, L., Blomqvist, C. and Elomaa, I. ( 2008) Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol26: 4289-4295.
60.
Saarto, T., Vehmanen, L., Elomaa, I., Valimaki, M., Makela, P. and Blomqvist, C. ( 2001) The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer . Br J Cancer84: 1047-1051.
61.
Santini, D., Martini, F., Fratto, M.E., Galluzzo, S., Vincenzi, B., Agrati, C. et al. (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother58: 31-38.
62.
Santini, D., Vincenzi, B., Galluzzo, S., Battistoni, F., Rocci, L., Venditti, O. et al. (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res13: 4482-4486.
63.
Schenk, N., Lombart, A., Frassoladti, A., Neven, P., Jerusalem, G., Deleu, I. et al. (2007) The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur J Cancer Suppl5: 186-187, Abstract 2008.
64.
Shapiro, C.L., Halabi, S., Gibson, G., Hars, V., Weckstein, D.J., Kirshner, J. et al. (2008). Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. Oral session presented at: 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago, IL, Abstract 512.
65.
Shapiro, C.L., Manola, J. and Leboff, M. ( 2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol19: 3306-3311.
66.
Singh, S., Cuzick, J., Edwards, R., Blake, G., Truscott, J., Coleman, R. et al. (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Breast Cancer Res Treat106(suppl 1): S9, Abstract 28.
67.
Siris, E.S., Chen, Y.-T., Abbott, T.A., Barrett-Connor, E., Miller, P.D., Wehren, L.E. et al. (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med164: 1108-1112.
68.
Solomayer, E.F., Gebauer, G., Hirnle, P., Janni, W., Lück, H.-J., Becker, S. et al. (2009) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res69(suppl): 170s-171s, Abstract 2048.
69.
Van Poznak, C., Hannon, R.A., Clack, G., Campone, M., Mackey, J.R., Apffelstaedt, J. et al. (2007) The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Breast Cancer Res Treat106(suppl 1): S37, Abstract 502.
70.
Vehmanen, L., Saarto, T., Elomaa, I., Makela, P., Valimaki, M. and Blomqvist, C. ( 2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer37: 2373-2378.
71.
Warming, L., Hassager, C. and Christiansen, C. ( 2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int13: 105-112.
72.
Winer, E.P., Hudis, C., Burstein, H.J., Wolff, A.C., Pritchard, K.I., Ingle, J.N. et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol23: 619-629.
73.
Winter, M.C., Holen, I. and Coleman, R.E. ( 2008a) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev34: 453-475.
74.
Winter, M.C., Thorpe, H., Burkinshaw, R., Beevers, S. and Coleman, R.E. ( 2008b). The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer. Oral session presented at: San Antonio Breast Cancer Symposium; December 10-14; San Antonio, Texas.
